Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688443 Chongqing Genrix Biopharmaceutical Co Ltd SHSE:688443
29 GF Score
Price ¥26.36
! 4 Warning Signs
View Full Analysis

What is Chongqing Genrix Biopharmaceutical Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

SHSE:688443
29GF Score
Chongqing Genrix Biopharmaceutical Co Ltd SHSE:688443
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chongqing Genrix Biopharmaceutical Co Business Description

Address No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan District, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
29GF Score

Get the complete analysis for SHSE:688443

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.36
Price